HLA

Gene

Related News

CRISPR Therapeutics says CASGEVY momentum is building as zugo-cel and other pipeline data near

May 16, 2026

CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.

Personalized mRNA Vaccine Induces Durable T Cell Responses in Triple-Negative Breast Cancer

Feb 24, 2026

A first-in-human trial shows individualized neoantigen mRNA vaccines generated multi-year T cell responses in early-stage TNBC patients, with 82.9% of targeted mutations eliciting measurable immune activation not detectable before vaccination.